Cftr Trikafta denied due to quantity / dose limits by Humana?

Humana's specific coverage criteria for cftr trikafta are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana May Limit the Quantity of Trikafta — and Why That Decision Is Appealable

Trikafta (elexacaftor/tezacaftor/ivacaftor) is an FDA-approved CFTR modulator combination used in cystic fibrosis (CF). Humana's quantity-limit edits on this medication are typically based on dispensing-increment or days-supply rules written into its pharmacy benefit policy. Because Trikafta is taken on a fixed daily regimen as specified in the FDA-approved prescribing label, quantity restrictions that fall short of a standard treatment supply can constitute a clinically inappropriate barrier — and that makes the denial a strong candidate for reversal.

## Why This Denial Happens

Insurers apply quantity limits to manage cost and prevent stockpiling. For specialty medications like Trikafta, limits are sometimes set at intervals that do not align with the prescribed days-supply or with standard specialty-pharmacy dispensing practice. When a limit is triggered, the claim is automatically denied rather than reviewed for individual medical necessity.

## Your Federal Appeal Rights

• Internal appeal: You have the right to a full internal appeal under ERISA §503 (employer plans) or applicable state law (individual/fully-insured plans). Submit within the timeframe shown on the denial letter, typically 180 days.
• External review: Under ACA §2719, you may request an independent external review after exhausting the internal process — or, in urgent situations, concurrently. The external reviewer is not employed by Humana and must follow medical evidence standards.
• Expedited review: If the standard timeline would seriously jeopardize your health, request an expedited internal and/or expedited external review. Decisions on expedited reviews are required within 72 hours.
• Window: Most external-review requests must be filed within approximately four months of the final internal denial, but confirm the exact deadline printed on your denial letter.

## Documentation to Gather

1. Diagnosis confirmation — pulmonologist notes confirming CF diagnosis and CFTR mutation type (Trikafta is approved for specific mutation classes; confirm yours meets the label indication). 2. Prescriber medical-necessity letter — a detailed letter from your CF specialist explaining why the prescribed quantity and days-supply are medically required per the FDA label and applicable CF care guidelines (such as those from the Cystic Fibrosis Foundation). 3. Treatment history — records showing current Trikafta use, clinical response (lung function trends, pulmonary exacerbation history), and the impact any supply interruption would have. 4. Dispensing documentation — specialty pharmacy correspondence confirming standard dispensing practice for this medication class.

## Criteria-Mapping Structure

For the strongest appeal, obtain Humana's current published drug quantity-limit policy for Trikafta and the FDA-approved prescribing label. Then build a point-by-point response:

| Policy Requirement | Evidence in Your Chart / Letter | |---|---| | Each quantity criterion listed in Humana's policy | Specific chart entry or prescriber statement that satisfies it | | FDA label indication confirmation | Documented mutation type matching label | | Days-supply standard per specialty pharmacy practice | Specialty pharmacy attestation |

Submit this mapping as the body of your appeal letter so the reviewer can verify compliance without searching through attachments.